Acceptable changes in quality attributes of glycosylated biopharmaceuticals - Wikidata - awgldk - TriplyDB

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

http://www.wikidata.org/entity/Q28235143

about

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases Glycotherapy: new advances inspire a reemergence of glycans in medicine Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges Biosimilar: what it is not Glycan analysis of therapeutic glycoproteins In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers.Clinical considerations for biosimilar antibodies.Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary?High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.Biosimilars: Implications for health-system pharmacists.PCR on yeast colonies: an improved method for glyco-engineered Saccharomyces cerevisiae.Etanercept biosimilars Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies Advanced mass spectrometry workflows for analyzing disulfide bonds in biologics.Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.Emerging technologies for making glycan-defined glycoproteins The economic pressures for biosimilar drug use in cancer medicine Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Current status and future prospects for biologic treatments of psoriasis.Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports.A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines.Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Transgenesis applied to goat: current applications and ongoing research.Rituximab biosimilars.Proposal for a new nomenclature of disease-modifying antirheumatic drugs.Drift, evolution, and divergence in biologics and biosimilars manufacturing.Future directions in inflammatory bowel disease management.The ESA scenario gets complex: from biosimilar epoetins to activin traps.Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.

P2860

Q27013577-34CE97DB-FC17-44E0-9F28-C289C0ED80FD Q27027997-92665924-CE7A-4F82-B4B1-B41F62168CF7 Q28066776-8D1A2454-6B24-4255-A3C8-B2ACB3EC9A8D Q28079835-CE877FBD-88F6-4691-BE3E-21C475CAF4A9 Q28080880-65C42C9F-8A0E-491C-9B35-9A7FC1E4A852 Q28082842-3836EAF5-647A-4CCE-8FFC-0ADABB251C37 Q28547176-A5880CF7-A913-4A9F-BCD1-184DC1205772 Q30355888-DFD4F53D-A2D9-4396-ADF5-B3150F94449C Q30377239-2F1755E7-9643-4E7F-8CE6-97D17F265C57 Q30377369-B022D088-FDA7-48CE-B737-9A3B43766CAD Q30594813-ADB77555-DA78-4FA1-B77D-9A2AAE4FE40A Q30675226-57F0E1A4-E9BC-44E6-A240-DDAC2B9E956D Q34372394-E640F473-314B-4B4D-A471-EEC1C87BFEC6 Q34728849-9D6D6BE1-5079-49A7-AB9F-66B372A4EC6D Q35020358-347E7BBC-D1C6-475A-97CA-1E74474B68C1 Q35129041-970DE2A7-2E89-4268-89E3-5EF431814785 Q35568366-FE119175-6ACC-48EF-95B0-AB4A50EF9BD0 Q35589350-3797E543-E62D-464D-9062-B1136A034716 Q35685635-2D9B388D-3F37-4CBD-8FA3-0C9E663E0311 Q35795204-5EBF69FD-42A5-4135-933D-C6239B9625ED Q35803387-923BE982-47F1-4D36-A31E-E5C6798FFE20 Q35835005-CC0D9EDE-3D8A-46D0-BA37-7370C740FB16 Q35918874-036A5CB0-4288-49BA-A6CF-8008681A49E8 Q35992488-E63DA92F-7C47-4A53-BA71-F81409229259 Q36057909-B7D5687D-7AC7-4D5E-B613-7DC6F71B3805 Q36189447-6F721546-3517-41A9-812D-8B3759065173 Q36385526-497A51DD-82A7-414D-8D70-EF184F6E2AF8 Q36411858-2E94B617-04B0-401A-BC45-19D607D15385 Q36526958-1C2C41CF-D3A0-4187-A25A-1D81E5AAEDF8 Q36588710-83EA1D5E-7107-4315-BFFB-81F1BD1EC490 Q37022207-BF898DCF-916E-49D9-8DB4-F6E4FF1F67F6 Q37704338-1BAAB7B1-6ABF-456A-B99C-181BD3F44DD0 Q37999380-7FDF573F-AE86-43AA-B80C-884632D56E46 Q38005004-891AF018-0CA4-452A-B400-1437CA09FBFB Q38100232-801166DE-E476-4E83-B184-09ADCE70304A Q38144973-92B418B8-1D97-48D1-9718-F02A55D4A418 Q38190917-E2E45F5D-A945-4F57-AB31-8233BFE324A1 Q38205305-15C79DDB-8525-4B6D-9318-97D2077B10C4 Q38205752-4374C8D5-B987-4DA0-943A-806142E49103 Q38209872-E0814506-D7B6-4E96-9815-B8FCC8798CB7

P2860

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

http://www.wikidata.org/entity/Q28235143

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@ast

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@en

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@nl

type

label

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@ast

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@en

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@nl

prefLabel

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@ast

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@en

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@nl

P1433

Q28235143-4D519019-6928-469C-B634-68D7C1686AD6

P1476

Q28235143-95B007FB-F752-4EA2-ABD1-1EF6256B05C4

P2093

Q28235143-769DB552-AD86-4D16-A5D7-C413CE4B2109

Q28235143-812291C5-1F97-4955-BDF6-C2B2D1E0466C

Q28235143-A55F8880-B691-4DF1-A98A-78659BD628CE

Q28235143-AA899CF4-02E5-4ECB-B3A0-03C6B572B8D6

Q28235143-CDE08559-1558-43F5-950E-3FD200121D04

Q28235143-D42F7788-FA9C-4DA9-A3E8-DF15BCA2E067

P2860

Q28235143-21059A6C-7D57-43AE-878E-B6280F93CB82

Q28235143-3119E318-8715-4443-84CC-1F1C906E1CA8

Q28235143-54061F25-5AE4-478B-A256-A6F2F5EFE077

Q28235143-64B13A71-9972-47C6-B093-F5A2C517D68B

Q28235143-9B0AF762-45FC-43D1-B974-A07185812A34

Q28235143-9FD01B59-397E-4461-B69E-A7E48D4E91E4

Q28235143-AFB27DD3-8DEB-4E40-9FF6-5F7E8B33E303

Q28235143-C9C79DE1-03BD-436D-95C5-99E59E5B0F52

P2888

Q28235143-D5B48E72-571E-4E13-97FA-5B32BC3F9005

P304

Q28235143-276CE926-709A-4068-9778-05C9B053FF91

P31

Q28235143-8E592550-566C-4F9D-BD7D-7A4180277582

P3181

Q28235143-01FDD753-9977-4A73-8EC9-74CED2D85E88

P356

Q28235143-FBCB6515-59CC-416B-B029-BC9811ECA8DE

P407

Q28235143-92823401-5AB6-47A3-8D3B-50957688FB39

P433

Q28235143-946F97DB-0389-4BAA-8863-8C3EBD25159F

P478

Q28235143-025BB675-CEDD-438E-965C-7568AFA72A98

P577

Q28235143-91909E60-4AB0-40D6-88A7-A00312B41937

P6179

Q28235143-9EBA6662-CA62-4E5D-95DA-9C9855F1749A

P698

Q28235143-4D15853C-6527-44B4-83B8-4E48C6BAE634

P921

Q28235143-D32C2113-CC36-41A3-977A-67731C4E2525

P3181

P356

P1433

Nature Biotechnology

P1476

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

@en

P2093

Claudia Torella

http://www.w3.org/2001/XMLSchema#string

Hansjörg Toll

http://www.w3.org/2001/XMLSchema#string

Martin Schiestl

http://www.w3.org/2001/XMLSchema#string

Roger Grau

http://www.w3.org/2001/XMLSchema#string

Tadej Cepeljnik

http://www.w3.org/2001/XMLSchema#string

Thomas Stangler

http://www.w3.org/2001/XMLSchema#string

P2860

Development and characterization of novel erythropoiesis stimulating protein (NESP)

Characterizing biological products and assessing comparability following manufacturing changes.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.

Mechanisms of killing by anti-CD20 monoclonal antibodies.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Understanding and circumventing resistance to anticancer monoclonal antibodies.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.

P2888

P304

310-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

791110

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NBT.1839

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027451900

http://www.w3.org/2001/XMLSchema#string

P698

21478841

http://www.w3.org/2001/XMLSchema#string

P921